Venmax Drugs Peer Comparison

BSE: 531015

₹14.75

₹0.63 (4.46%)

As on 04-Sep-2026IST

Market cap

₹21 Cr

Revenue (TTM)

₹9 Cr

P/E Ratio

76

P/B Ratio

1

Div. Yield

0 %

Edit

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	21	33,908	29,353	28,517	25,923
Revenue (₹ Cr)	9	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	0.28	414.00	288.22	-371.81	387.35
Net Margin (%)	2.97	11.23	14.79	-3.93	26.01
RoE (%)	2.30	8.38	29.77	-3.85	25.18
Price to Earnings	76.03	82.90	101.84	--	67.12
Price-To-Book	1.03	6.74	21.87	3.56	15.02

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	9.29	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	9.45	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	9.14	2,792.00	1,485.56	8,195.15	919.25
EBITDA	0.16	772.00	450.24	1,010.13	542.56
Depreciation	0.00	226.00	50.83	857.51	37.68
EBIT	0.15	546.00	399.41	152.62	504.88
Interest	0.00	217.00	40.84	342.73	3.77
Other Income	0.16	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	0.31	463.00	371.35	-162.68	528.56
Provision for Tax	0.03	49.00	83.14	209.13	141.21
Profit after Tax	0.28	414.00	288.22	-371.81	387.35

Liabilities (₹ Cr)

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	15.01	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.00	1,712.00	202.03	5,044.14	42.40
Current Liabilities	1.82	1,622.00	835.87	4,758.28	230.82
Total Liabilities	5.17	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	0.04	5,343.00	519.60	10,211.52	1,026.85
Current Assets	16.79	2,606.00	1,681.81	7,191.66	881.27
Total Assets	5.17	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	0.05	1,859.00	393.17	4,720.27	8.18
Net Current Assets	14.97	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-2.29	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	--	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	4.77	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	2.48	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-0.64	4.07	26.97	6.61	20.14
ROE (%)	2.30	8.38	29.77	-3.85	25.18
ROA (%)	2.35	4.94	24.77	-2.21	21.93
EBIT Margin (%)	1.62	15.32	20.63	1.66	34.54
Net Margin (%)	2.97	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	385.78	18.37	46.65	0.78	40.90
EBIT Growth (%)	114.91	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	2,241.67	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	1,251.11	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	-1.62	29.77	42.49	2.28	94.96

Valuation Ratios

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	47.66	85.09	100.28	-91.14	67.12
Price / Book Value	1.03	6.74	21.87	3.56	15.02
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	122.14	45.82	65.00	32.33	47.41
Market Cap (₹ Cr)	14.94	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.01	0.11	0.54	0.12	0.02
Current Ratio	9.24	1.61	2.01	1.51	3.82
Quick Ratio	8.04	1.06	1.14	0.87	2.82
Interest Coverage	311.00	3.13	10.09	0.53	141.16

Operating Efficiency Ratios

	Venmax Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	17.32	16.50	26.28	23.44	24.80
Asset Turnover	0.78	0.43	1.66	0.55	0.83
Receivable days	430.69	60.36	47.59	77.05	90.06
Inventory Days	26.00	64.42	62.58	77.13	61.02
Payable days	168.15	218.94	228.78	173.49	96.06
Cash Conversion Cycle	288.55	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly